GHAPPcast5 Feb 2025

FAQ: How can physicians better care for patients with cirrhosis?

Sherona Bau, NP, at Pfleger Liver Institute, discusses the importance of providing effective care for patients with cirrhosis, which requires a proactive and comprehensive approach from healthcare providers, including physicians and advanced practice providers. Early diagnosis is crucial, as many patients with compensated cirrhosis remain asymptomatic. Using non-invasive testing, such as FibroScan or morphology imaging, can help identify liver damage and make a timely diagnosis.

Once cirrhosis is diagnosed, patient education becomes essential. Providers should emphasize the importance of abstinence from alcohol, as patients may unknowingly continue drinking if unaware of their condition. It is also vital to stress adherence to medications like lactulose to prevent complications such as hepatic encephalopathy. Additionally, patients should undergo liver cancer screening every six months through abdominal ultrasound and alpha-fetoprotein testing, as cirrhotic patients are at higher risk for liver cancer.

Preventive care, such as vaccinations for flu, hepatitis A, and hepatitis B, should also be part of the treatment plan. For patients whose cirrhosis is alcohol-related, referring them to addiction medicine can help address alcohol cravings and support long-term recovery. By fostering a non-judgmental, communicative approach, healthcare providers can build trust, encourage adherence to treatment plans, and ensure timely follow-up appointments. These steps can significantly improve care for patients living with cirrhosis. For more information visit the GHAPP website or download the GHAPP ACE mobile app.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(155)

FAQ: QUASAR Long Term Extension Interim Analysis

Thank you to Johnson & Johnson for their support on this FAQ Video Module. In this educational video, Jamie Brogan, APRN, from Northwestern Medicine, reviews the latest QUASAR long-term extension data...

2 Jun 4min

Medication Review: Guselkumab IV vs SC Formulation

Thank you to Johnson & Johnson for their support on this Medication Review Video Module. In this quick educational video, Angelina Collins, NP, from the University of California San Diego Inflammatory...

28 Mai 3min

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

Thank you to Salix for the support on this FAQ Video Module.This educational FAQ module, featuring Mikhail Alper, PA-C focuses on recognizing risk factors and early clinical indicators of Overt Hepati...

26 Mai 2min

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

Thank you to Johnson & Johnson for the support on this FAQ Video Module.This FAQ video features Janette Villalon, PA, who reviews the role of guselkumab in treating extraintestinal manifestations in p...

19 Mai 5min

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the evolving role of monotherapy versus combination therapy in the treatment of inflammato...

14 Mai 3min

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the role of stable pharmacokinetics (PK) in achieving continuous inflammatory control in i...

7 Mai 6min

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Thank you to Johnson & Johnson for the support on this Journal Club Review Module.In this journal club video, Sharon Dudley Brown, CRNP, PhD, from the IBD Center at Johns Hopkins University, reviews t...

28 Apr 5min

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Thank you to AbbVie for the support on this Journal Club Review Module.This journal club review episode explores the benefit–risk profile of Upadacitinib for patients with moderately to severely activ...

21 Apr 23min